医药导报2011，Vol.30Issue(9)：1160-1162,3.DOI:10.3870/yydb.2011.09.014
紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌17例
17 Cases of Advanced Non-small-cell Lung Cancer Treated with Paclitaxel Liposome plus Nedaplatin
摘要
Abstract
0bjective To evaluate the efficacy and toxicity of paclitaxel liposome plus nedaplatin in the treament of advanced non-small cell lung cancer(NSCLC). Methods 17 cases of NSCLC treated with paclitaxel liposome and nedaplatin for2 to6 cycles, by infusing paclitaxel liposome 135 mg (m2)-1 for3 h on dayl and combining nedaplatin 80 mg (m2)-1 as infusion on day2. Results Among17 patients being evaluated for response to treament, 1 showed complete response(CR),4 showed partial response(PR), 3 shewed stable disease( SD), 9 showed progress disease(PD). The main side reaction was haematological toxicity, including neutropenia and thromboeytopenia The non-haemutological toxicity was nausea and vamiting,mild liver injury. and fair loss Conclusion Paclitaxel Iiposome plus nedap latin was effective and well tolerated for treating patients with advanced non-small cell lung cancer关键词
紫杉醇脂质体/奈达铂/癌,非小细胞肺Key words
Paclitaxel liposome/ Nedap latin/ Non-small-cell lung cancer分类
医药卫生引用本文复制引用
张金忠,戈伟,郑永法..紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌17例[J].医药导报,2011,30(9):1160-1162,3.
